Beam Therapeutics Price Target Cut to $31.00/Share From $33.00 by Barclays
Beam Therapeutics Is Maintained at Equal-Weight by Barclays
Express News | RBC Capital Reiterates Sector Perform on Beam Therapeutics, Maintains $27 Price Target
Beam Therapeutics Analyst Ratings
Beam Therapeutics (BEAM) Q2 Earnings Beat, Revenues Miss
Analysts Conflicted on These Healthcare Names: Nyxoah (NYXH), MultiPlan (MPLN) and Beam Therapeutics (BEAM)
Barclays Keeps Their Hold Rating on Beam Therapeutics (BEAM)
Express News | Beam Therapeutics Inc : JP Morgan Raises Target Price to $48 From $45
Beam Therapeutics Shares Edge Higher Despite Wider Q2 Loss, Lower Revenue
Beam Therapeutics' Advancements Bolster Buy Rating: Momentum in Gene Editing Trials and Regulatory Progress
Beam Therapeutics | 10-Q: Q2 2024 Earnings Report
Express News | Beam Therapeutics: U.S. FDA Cleared Investigational New Drug Application for Beam-301 in Glycogen Storage Disease Type Ia
Express News | Beam Therapeutics: Ended Q2 With $1 Bln in Cash, Cash Equivalents & Marketable Securities; Expected Operating Runway Into 2027
Beam Therapeutics 2Q Loss/Shr $1.11 >BEAM
Express News | Beam Therapeutics Q2 Operating Expenses USD 116.667 Million
Express News | Beam Therapeutics Q2 Net Income USD -91.051 Million Vs. IBES Estimate USD -103 Million
Express News | Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?
IBM Posts Upbeat Earnings, Joins ServiceNow, Helmerich & Payne, RTX, Nasdaq And Other Big Stocks Moving Higher On Thursday